Industry News

Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second quarter ended June 30, 2016.. Total revenues were $39.1 million as compared to $35.2 million in the second quarter of 2015. Solana ® Trichomonas assay received CE Mark. Sofia ® Strep A+ FIA approved in Japan. Sofia ® Influenza A+ B FIA approved in Singapore. Sofia ® hCG FIA..."/>
Quidel Reports Second Quarter 2016 Financial Results
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that, as anticipated, it received written communication from the U.S. Food and Drug Administration outlining information required to resolve the clinical hold for its Investigational New Drug for RG-101, which was announced on June 27, 2016.. In the written communication, the FDA..."/>
Regulus Provides Update on Clinical Hold of RG-101
McKesson Reports Fiscal 2017 First-Quarter Results
Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis ® technology platform, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All of the securities to be sold in the offering will be offered..."/>
Argos Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Varian Medical Systems today is reporting GAAP net earnings of $1.04 per diluted share and non-GAAP net earnings of $1.22 per diluted share for the third quarter of fiscal year 2016. Varian's revenues totaled $789 million for the third quarter, up 1 percent from the year-ago quarter in dollars and even with the year-ago quarter in constant currency. The company ended the quarter with a $3.3 billion backlog, up 5 percent from the end of the..."/>
Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2016
Kite Pharma, Inc., a clinical-stage biopharmaceutical company focused on developing engineered autologous T-cell therapy products for the treatment of cancer, today announced that the Company has entered into an exclusive, worldwide license with the National Institutes of Health for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies."/>
Kite Pharma Announces Exclusive License with the National Institutes of Health for Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) Product Candidate to Treat B-Cell Malignancies
Anika Therapeutics, Inc., a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today reported financial results for the second quarter ended June 30, 2016, along with business progress in the period. “We continued our strong momentum in the second quarter, with total revenue growth of 16% year- over-year for the quarter,” said Charles H...."/>
Anika Reports Second Quarter 2016 Financial Results
Vascular Solutions, Inc. today announced that the Company is scheduled to present at the Canaccord Genuity Growth Conference in Boston on Wednesday, August 10th at 8:00am.. Howard Root, Chief Executive Officer of Vascular Solutions, will deliver the Company’ s presentation. To hear the live audio webcast of the Vascular Solutions’ presentation, go to the investor relations page of the Company’ s web site www.vasc.com and click on the“ Investor Conferences”..."/>
Vascular Solutions to Present at the Canaccord Genuity Growth Conference
Depomed, Inc. today announced that it will release second quarter fiscal year 2016 financial results after the close of market, Wednesday, August 3, 2016. The Company will host a conference call beginning at 4:30 p.m. EDT to discuss its results.. Participants can access the call by dialing 839-0046 or 270-6032."/>
Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016
ICAD Reports Second Quarter 2016 Financial Results
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, today announced that three abstracts have been selected for presentation at the European Society of Medical Oncology 2016 annual meeting held October 7-11, 2016..."/>
Karyopharm to Present Updated Phase 2 Clinical Data from SIGN Study at European Society of Medical Oncology 2016 Annual Meeting
LeMaitre Vascular, Inc., a provider of vascular devices, today reported Q2 2016 results, provided increased guidance, announced a $0.045/ share dividend and authorized a $5.0 mm share repurchase program.. Record sales of $22.4 mm, +13% vs. Q2 2015 Gross margin of 68.6% vs. 66.0% Record op. income of $3.8 mm vs. $2.8 mm, +35% Op. margin of 17% vs. 14% Record net income of $2.6 mm vs. $1.8 mm, +47% Record earnings of $0.14 per diluted share vs. $0.10, +40% Record EBITDA of..."/>
LeMaitre Q2 2016 Record Sales $22.4mm (+13%), Record Op. Income $3.8mm (+35%)
Entellus Medical, Inc., a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced the company plans to participate in the 36 th Annual Growth Conference hosted by Canaccord Genuity in Boston, MA.. Entellus Medical’ s management is scheduled to present on Wednesday, August 10, 2016 at..."/>
Entellus Medical to Present at the Canaccord Genuity Growth Conference
Sangamo BioSciences, Inc., the leader in therapeutic genome editing, announced today that the company will release its second quarter 2016 financial results after the market closes on Wednesday, August 3, 2016. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the quarter's financial results and discuss..."/>
Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast
NOVADAQ Technologies Inc., the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its second quarter ended June 30, 2016. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States dollars.. For the three months ended June 30, 2016, NOVADAQ reported revenues of $20.1 million, an increase of 34%..."/>
NOVADAQ Reports Second Quarter 2016 Financial Results
Vertex Reports Second Quarter 2016 Financial Results
Exact Sciences Corporation today announced an agreement to sell 7,000,000 shares of its common stock to Jefferies LLC, Robert W. Baird& Co. Incorporated and Canaccord Genuity Inc. as underwriters in an underwritten public offering pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares."/>
Exact Sciences Announces Agreement to Sell 7,000,000 Common Shares
Amgen today announced financial results for the second quarter of 2016. Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion. Product sales grew 5 percent driven by Enbrel ®, Prolia ®, KYPROLIS ® and XGEVA ®. GAAP earnings per share increased 15 percent to $2.47 driven by higher revenues and higher operating margins. GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin..."/>
Amgen Reports Second Quarter 2016 Financial Results
Invuity, Inc., a leading surgical photonics company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Invuity expects to grant the underwriters a 30- day option to purchase additional shares of its common stock.. Invuity intends to use the net proceeds from the offering for continued expansion of its sales and marketing activities, investments in..."/>
Invuity Announces Proposed Public Offering of Common Stock
Hologic, Inc. announced today the Company's financial results for the fiscal third quarter ended June 25, 2016. GAAP diluted earnings per share of $0.30 increased 200% compared to the prior year period, and non-GAAP diluted EPS of $0.51 increased 18.6%. Revenue of $717.4 million increased 3.4%, or 3.6% in constant currency terms. "We posted very good results across the board in our fiscal third quarter," said Steve MacMillan, Hologic's..."/>
Hologic Announces Financial Results for Third Quarter of Fiscal 2016
Fibrocell Science, Inc. today announced that the first two adult subjects were enrolled in the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa. FCX-007 is Fibrocell’ s orphan gene-therapy product candidate for the treatment of RDEB, a devastating, painful, blistering skin disease with a high mortality rate.. “Enrollment of the first patients is an important milestone for Fibrocell and the RDEB..."/>
Fibrocell Announces First Subjects Enrolled in Phase I/II Clinical Trial of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Nuvectra Corporation, a neurostimulation medical device company, announced today that it will release its financial results for the second quarter ended July 1, 2016 on Wednesday, August 10, 2016 after the market close.. Nuvectra will hold a conference call on Wednesday, August 10, 2016 at 4:30pm ET to discuss the results. The dial in numbers are 514-4518 for domestic callers and 815-5850 for international callers."/>
Nuvectra to Report Second Quarter 2016 Financial Results on August 10, 2016
Vanda Pharmaceuticals Inc., today announced financial and operational results for the second quarter ended June 30, 2016.. "Vanda's commercial business continues to demonstrate strong progress and growth," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "We look forward to our planned launch of HETLIOZ in Germany in the third quarter and the opportunity to bring an important therapy to Non-24 patients in Europe.""/>
Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology685 Articles
Financials667 Articles
Consumer Discretionary610 Articles
Industrials460 Articles
Health Care409 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.